bioMérieux S.A.

Paris Stock Exchange BIM.PA

bioMérieux S.A. Receivables for the year ending December 31, 2023: USD 0.00

bioMérieux S.A. Receivables is USD 0.00 for the year ending December 31, 2023, a -100.00% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

bioMérieux S.A. Receivables for the year ending December 31, 2022 was USD 925.71 M, a 14.70% change year over year.
bioMérieux S.A. Receivables for the year ending December 31, 2021 was USD 807.09 M, a -4.18% change year over year.
bioMérieux S.A. Receivables for the year ending December 31, 2020 was USD 842.27 M, a 15.95% change year over year.
bioMérieux S.A. Receivables for the year ending December 31, 2019 was USD 726.42 M, a 29.06% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Paris Stock Exchange: BIM.PA

bioMérieux S.A.

CEO	Mr. Pierre Boulud
IPO Date	July 7, 2004
Location	France
Headquarters	376 Chemin De l'Orme
Employees	13,409
Sector	Healthcare
Industries Biotechnology Cleaning Supplies Medical Instruments Personal Care Pharmaceuticals Plastics

Description

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Key trends

Past 5 years